HC Wainwright Has Optimistic Outlook of VIR FY2025 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR) – Analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Vir Biotechnology in a note issued to investors on Tuesday, December 30th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($2.98) for the year, up from their prior estimate of ($3.45). HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2025 earnings at ($0.13) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($1.90) EPS, FY2028 earnings at ($1.40) EPS and FY2029 earnings at ($1.13) EPS.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.98 million. During the same period last year, the business earned ($1.56) earnings per share. The firm’s revenue was up .8% on a year-over-year basis.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.30.

Vir Biotechnology Stock Performance

VIR stock opened at $6.03 on Thursday. The firm’s fifty day moving average is $5.99 and its 200 day moving average is $5.52. Vir Biotechnology has a one year low of $4.16 and a one year high of $14.45. The firm has a market cap of $838.89 million, a PE ratio of -1.67 and a beta of 1.39.

Insiders Place Their Bets

In other Vir Biotechnology news, CFO Jason O’byrne sold 6,799 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $5.56, for a total transaction of $37,802.44. Following the sale, the chief financial officer owned 110,701 shares in the company, valued at $615,497.56. This represents a 5.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Endurance (Cayman) Ltd Svf sold 191,854 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $5.98, for a total value of $1,147,286.92. Following the transaction, the insider directly owned 13,728,924 shares of the company’s stock, valued at approximately $82,098,965.52. This represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,559,324 shares of company stock worth $15,659,663 in the last quarter. 16.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vir Biotechnology

Several hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. boosted its holdings in shares of Vir Biotechnology by 11.7% in the 1st quarter. American Century Companies Inc. now owns 257,620 shares of the company’s stock valued at $1,669,000 after buying an additional 26,896 shares in the last quarter. Ieq Capital LLC acquired a new position in Vir Biotechnology in the first quarter valued at $230,000. Graham Capital Management L.P. boosted its stake in Vir Biotechnology by 41.7% in the first quarter. Graham Capital Management L.P. now owns 115,115 shares of the company’s stock valued at $746,000 after acquiring an additional 33,865 shares in the last quarter. Allostery Investments LP purchased a new position in shares of Vir Biotechnology during the first quarter worth about $144,000. Finally, AQR Capital Management LLC increased its position in shares of Vir Biotechnology by 2,088.4% during the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock worth $1,739,000 after purchasing an additional 256,037 shares in the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: HC Wainwright raised multiple near‑term EPS forecasts (Q1–Q4 2026) and lifted FY2026 estimates (FY2026 now -$2.16 vs prior -$2.40), and dramatically raised Q4 2025 from -$0.59 to -$0.13 — signaling smaller expected losses; the firm keeps a “Buy” rating and $15 price target, providing a clear upside reference for investors. MarketBeat: HC Wainwright raises estimates
• Neutral Sentiment: A broader media roundup (MSN) published a “3 ‘Strong Buy’ stocks to buy now” piece on 12/30; broader analyst/media attention can increase visibility and trading interest if Vir is highlighted. MSN: 3 ‘Strong Buy’ stocks to buy now

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.